A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer

AK104 (10mg/kg, q3w) + cisplatin weekly or every 3 weeks + radiotherapy (pelvic external beam radiotherapy + brachytherapy) until disease progression, intolerable toxicity, or the investigator judgment that the participant can no longer benefit, participant withdrawal of consent, or completion of 2 years of AK104 treatment.